Free Trial
NASDAQ:XGN

Exagen (XGN) Stock Price, News & Analysis

Exagen logo
$5.15 +0.44 (+9.34%)
(As of 12/20/2024 05:17 PM ET)

About Exagen Stock (NASDAQ:XGN)

Key Stats

Today's Range
$4.72
$5.18
50-Day Range
$2.43
$6.00
52-Week Range
$1.30
$6.22
Volume
79,173 shs
Average Volume
55,508 shs
Market Capitalization
$90.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Buy

Company Overview

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Exagen Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
93rd Percentile Overall Score

XGN MarketRank™: 

Exagen scored higher than 93% of companies evaluated by MarketBeat, and ranked 74th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Exagen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Exagen has only been the subject of 1 research reports in the past 90 days.

  • Read more about Exagen's stock forecast and price target.
  • Earnings Growth

    Earnings for Exagen are expected to grow in the coming year, from ($0.87) to ($0.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Exagen is -5.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Exagen is -5.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Exagen has a P/B Ratio of 3.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.67% of the float of Exagen has been sold short.
  • Short Interest Ratio / Days to Cover

    Exagen has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Exagen has recently decreased by 9.06%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Exagen does not currently pay a dividend.

  • Dividend Growth

    Exagen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.67% of the float of Exagen has been sold short.
  • Short Interest Ratio / Days to Cover

    Exagen has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Exagen has recently decreased by 9.06%, indicating that investor sentiment is improving significantly.
  • MarketBeat Follows

    5 people have added Exagen to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Exagen insiders have sold 866.37% more of their company's stock than they have bought. Specifically, they have bought $68,297.00 in company stock and sold $660,000.00 in company stock.

  • Percentage Held by Insiders

    26.10% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    75.25% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Exagen's insider trading history.
Receive XGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter.

XGN Stock News Headlines

Exagen achieves key milestone with 1M patient tested by AVISE CTD
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Q3 2024 Exagen Inc Earnings Call
See More Headlines

XGN Stock Analysis - Frequently Asked Questions

Exagen's stock was trading at $1.99 on January 1st, 2024. Since then, XGN shares have increased by 158.8% and is now trading at $5.15.
View the best growth stocks for 2024 here
.

Exagen Inc. (NASDAQ:XGN) released its earnings results on Tuesday, November, 12th. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.02. The business earned $12.51 million during the quarter, compared to analysts' expectations of $13.55 million. Exagen had a negative trailing twelve-month return on equity of 92.58% and a negative net margin of 30.36%.

Exagen (XGN) raised $50 million in an IPO on Thursday, September 19th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. Cowen, Cantor and William Blair acted as the underwriters for the IPO.

Top institutional investors of Exagen include Stonepine Capital Management LLC (3.07%), Wasatch Advisors LP (2.82%), Perkins Capital Management Inc. (2.64%) and Palumbo Wealth Management LLC (0.44%). Insiders that own company stock include Nmsic Co-Investment Fund, LP, James L L Tullis, John Aballi, Kamal Adawi and Mark Hazeltine.
View institutional ownership trends
.

Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Exagen investors own include Chemours (CC), Ovintiv (OVV), Himax Technologies (HIMX), ImmunoGen (IMGN), Cassava Sciences (SAVA), CNX Resources (CNX) and Ford Motor (F).

Company Calendar

Last Earnings
11/12/2024
Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
NASDAQ:XGN
Fax
N/A
Employees
220
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+35.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-23,690,000.00
Pretax Margin
-30.30%

Debt

Sales & Book Value

Annual Sales
$55.75 million
Book Value
$1.33 per share

Miscellaneous

Free Float
13,034,000
Market Cap
$90.83 million
Optionable
Optionable
Beta
1.49
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NASDAQ:XGN) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners